Auauniversity

AUA2018 Take Home Messages Basic Sciences - Trauma by AUAUniversity

The Changing Landscape of Advanced Prostate Cancer Management: What You Need to Know is the first podcast in a 4-part series. Topics will include "Initial Management and Imaging of Advanced Prostate Cancer" and "Chemo-hormonal Therapy for Metastatic Hormone-Sensitive Prostate Cancer ". CME Available: https://auau.auanet.org/node/19906

This course will include short didactic lectures followed by case presentations to give attendees an understanding of the many new FDA-approved agents, as well as existing standard therapies, for advanced prostate cancer-both non-metastatic and metastatic CRPC. Particular attention will be devoted to sequencing the new agents and positioning them as compared to older existing therapies. The cost effectiveness of new and existing agents will also be addressed. CME Available: https://auau.auanet.org/content/novel-agents-concepts-management-hormone-na%C3%AFve-castrate-resistant-prostate-cancer-webcast

This course will provide a practical, evidence-based approach for the management of everyday problems in the management of prostate cancer, using a case-based approach with examples from real practice. Cases will illustrate contemporary management of early and late stage disease with emphasis on how new molecular diagnostic and prognostic tests (PCA3, MDx Confirm, Mitomics, Prolaris, Oncotype Dx Prostate, Decipher, and others) can be used for improved clinical decision making in screening, decisions on initial biopsy and rebiopsy, choosing and following men for active surveillance, and managing PSA failures. In addition, best practice use of newer agents for management of castrate-resistant disease will be reviewed, including the potential for use of targeted therapies based on genomic analysis of advanced tumors. The course will be of interest to individuals at all levels of clinical experience. CME Available: https://auau.auanet.org/content/management-prostate-cancer-case-based-approach-emphasis-integratin

The goal of the course is to provide both a basic and real-world application of immunotherapy for genitourinary oncology. The course is directed towards the urologist with an interest, but no prior experience delivering immunotherapy agents to patients with bladder and kidney cancer (with possible application to prostate cancer in the future). Starting with innovating breakthroughs, new therapies and their side-effects, the course will also cover common side-effects and biomarkers to risk stratify patients. We will plan to discuss real world-challenges in starting an immunotherapy program, from regulatory requirements to coding and billing for systemic therapies. CME Available: https://auau.auanet.org/content/immunotherapy-urologist-basic-principles-adverse-effects-drug-delivery-webcast-019ic-2018

This course will offer a review of what faculty believe are the most important articles in the English-speaking literature on prostate cancer from May 2017 to April 2018. Focus will be placed on articles that have relevance to clinical practice, including both research and clinical articles. CME Available: https://auau.auanet.org/content/prostate-cancer-update-webcast-063ic-2018

Review of current chemotherapy and immunotherapy regimens for genitourinary malignancies, including bladder, renal, and prostate cancers. Indications, outcomes, and toxicities will be discussed as well as clinical trial concepts. Survivorship issues will also be a focus of the session, which will include short, direct didactic lectures as well as a panel discussion with an interactive component. Standard of care chemotherapy regimens (eg MVAC for urothelial carcinoma) as well as newer immunotherapy options (eg checkpoint inhibition for renal cell carcinoma) will be included. Session objectives will include familiarity with systemic therapy regimens for these malignancies as well as their specific expected outcomes and side effects. CME Available: https://auau.auanet.org/content/chemotherapy-immunotherapy-options-genitourinary-malignancies-primer-advanced-practice

We will discuss common PSA dilemmas: 1. Who should be screened? 2. What is the role of MRI in biopsy naive and men with prior negative biopsy? 3. What other markers can be used to determine whether biopsy or rebiopsy is warranted? 4. Whats the optimal biopsy strategy: Transrectal, transperineal, MRI-cognitive, MRI fusion? 5. Discuss Active Surveillance, Rad Px, XRT and focal therapy pros and cons for PSA-detected cancer. 6. What is role of adjuvant v. salvage XRT post-RP? 7. Review new PET scans for biochemically recurrent disease after RP or XRT. 8. Discuss roles of ADT, chemotherapy, and other agents (PARP inhibitors, vaccines, immunooncologic agents) in men with advanced and metastatic disease. CME Available: https://auau.auanet.org/content/management-common-dilemmas-prostate-cancer-diagnosis-staging-treatment-webcast-058ic-2018

The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on: Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area. Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer. Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologist. CME: https://auau.auanet.org/content/highlights-renal-cell-carcinoma-coordination-care-patients-journey-2018

Much has been written and debated about drug treatment of overactive bladder (OAB) over the past two decades. Nevertheless, the field continues to evolve. OAB pharmacotherapy remains an area of active investigation and innovation. Patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms are important factors in improving patient outcomes. The publication of the recently updated AUA/SUFU Guideline entitled "Diagnosis and Treatment of Overactive Bladder (Non-neurogenic) in Adults, the proceedings of the 5th International Consultation on Incontinence," as well as European Association of Urology (EAU) Guidelines, has rekindled interest in this area. This course will describe the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy. Currently available agents as well as drugs in development will be discussed. CME Available: https://auau.auanet.org/content/contemporary-pharmaco

Dr. Nitti and Dr. Davis discus the use of focal therapy in the treatment of prostate cancer. @jdhdavis - This file has been updated

The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on: Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area. Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer. Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologists. CME: https://auau.auanet.org/content/highlights-renal-cell-carcinoma-evolving-landscape-adjuvant-therapy-2018

The "Live from AUA2018" Highlights in Renal Cell Carcinoma series is comprised of three panel discussions which will focus on: Discussing the evolving landscape of adjuvant therapy for the treatment of kidney cancer and debating the elements of disagreement in this area. Differentiating the roles of urologist and medical oncologist in the care of patients with kidney cancer. Appreciating the patient’s journey through RCC and identifying their needs as it relates to the coordination of care between the urologists and medical oncologist. CME Available: https://auau.auanet.org/content/highlights-renal-cell-carcinoma-roles-urologist-and-medical-oncologist-2018

This course will review the 2015 update to the 2013 AUA guidelines on castration-resistant prostate cancer. Faculty will explore the rigorous process used in the development of these evidence-based guidelines, as well as discuss new developments and future research needs for this topic. The course will showcase clinical scenarios in urological practice and the correct application of the new AUA guidelines in those instances. This course will be a benefit to practicing urologists, non-physician providers, residents preparing for their certification exam and physicians preparing for their re-certification exam. CME Available: https://auau.auanet.org/content/aua-castration-resistant-prostate-cancer-crpc-guidelines-webcast-074ic-2018

The American Urological Association (AUA) recognizes the critical role of the primary care provider in treating patients with urologic conditions. The AUA is pleased to offer this Podcast on one of the urologic topics most relevant to front-line patient care—Overactive Bladder (OAB). This OAB Podcast, recorded live at the 2018 AUA Annual Meeting, was recorded specifically for primary care providers and explores the following topics: the physiological and pharmacological underpinnings of modern drug treatment of overactive bladder including combination therapy; currently available agents as well as drugs in development; patient communication, including goal setting with respect to realistic expectations of therapy, and therapeutic algorithms; and more. Get the latest updates on this topic from the experts! You can also earn free CME for this Podcast! You can easily create an AUA account and earn free CME for this Podcast. Access at https://auau.auanet.org/AUA2018/contemporary-pharmacotherapy-oab-broadcast.

Steven A Kaplan, MD joins Dr. Nitti to discuss Minimally Invasive Treatment Of BPH. Dr. Kaplan is Professor of Urology at the Icahn School of Medicine at Mount Sinai and Director of Benign Urologic Diseases and The Men’s Health Program of the Mount Sinai Health System.

Dr Nitti and Dr. Daneshmand discuss the AUA Update Series Article titled "Update on Medical and Surgical Management of Advanced Testis Cancer" This episode will describe and explain the current recommendations for imaging; indications for post-chemotherapy retroperitoneal lymph node dissection; the IGCCCG (International Germ Cell Cancer Consensus Group) risk classification; and pros and cons of 3 cycles of cisplatin, etoposide and bleomycin vs 4 cycles of etoposide and cisplatin EP for IGCCCG good risk disease.

AUA2017 Court is in Session: Sepsis after Mini PNCL by AUAUniversity

Dr. Tanya D. Dorff presentation on Treatment Sequencing and Combinatorial Strategies in CRPC Acknowledgements The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support: Astellas AbbVie Genomic Health Sanofi Genzyme Tolmar Pharmaceuticals, Inc. CRPCProstate CancerAUA

Dr. Adam S. Kiebel presents a presentation on the 2017 AUA CRPC Guideline. Dr. Kibel is Chief of Urologic Surgery at both the Brigham and Women’s Hospital and Dana-Farber Cancer Institute in Boston, Massachusetts. In addition, he is Elliot Carr Cutler Professor of Surgery at Harvard University School of Medicine, Chairman of the Harvard Program in Urology Residency Program (Longwood) and Co-Leader of the Prostate Cancer Program for Dana Farber/Harvard Cancer Center. Dr Kibel received his undergraduate and medical degrees from Cornell University, completed his urology residency at the Harvard Urology Program, and his fellowship at the Brady Urologic Institute at Johns Hopkins in Baltimore, Maryland. Acknowledgements The AUA Office of Education would like to thank the companies who support continuing education of physicians. The AUA recognizes the following companies for providing educational grant support: Astellas AbbVie Genomic Health Sanofi Genzyme Tolmar Pharmaceuticals, Inc.